Abstract
Optogenetics provides exceptional spatial, temporal, and cell-type specificity for manipulating biological function, but the ability to produce a light-evoked response does not by itself establish therapeutic relevance. Disease-oriented studies now span molecular assembly, neuronal excitability, neuromuscular transmission, circuit modulation, engineered human tissues, closed-loop control, and early human intervention, yet these outcomes support fundamentally different levels of inference. Here, we critically examine optogenetic applications across neuromuscular and neurological disorders and propose an evidence-tiered framework for distinguishing mechanistic causality, disease-relevant functional validation, in vivo therapeutic modulation, integrated translational system validation, and human clinical proof-of-concept. Neuromuscular disorders illustrate how optogenetics can connect molecular mechanisms and activity-dependent phenotypes to human motor-unit function, whereas studies in Parkinson's disease, Alzheimer's disease, Huntington's disease, stroke, and epilepsy primarily define causal pathways, network states, stimulation rules, and opportunities for clinically feasible neuromodulation. Human-derived motor-unit systems, organoids, and other bioengineered platforms provide important functional de-risking but should not be equated with clinical evidence. Retinal optogenetics currently provides the clearest human proof-of-concept, while its favorable anatomy limits generalization to deeper or distributed neural targets. We further show that translational progression depends on coordinated optimization of gene delivery, actuator performance, optical dosimetry, material-tissue compatibility, implant mechanics, sensing and feedback control, durability, safety, and clinically meaningful advantage over established therapies. Accordingly, optogenetic translation should be viewed as a coupled gene-material-device-control problem rather than as optical stimulation alone. This framework clarifies what different experimental designs demonstrate, where evidence remains incomplete, and which biological and engineering barriers must be resolved before optical specificity can be converted into durable clinical benefit.